Supporting the FDA’s tougher stance on unproven cell therapies: an interview with Massimo Dominici
In this interview, Massimo Dominici, ISCT past president, comments on the FDA’s recent statement on ‘unproven’ cell therapies.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.